Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00211250
Other study ID # JCCR-001
Secondary ID
Status Completed
Phase Phase 4
First received September 13, 2005
Last updated January 27, 2009
Start date July 2005
Est. completion date September 2006

Study information

Verified date January 2009
Source Joliet Center for Clinical Research
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Interventional

Clinical Trial Summary

The purpose of this study is to compare compliance, tolerability, effectiveness, and side-effects in Bipolar I and II patients switching from Valproic Acid to Depakote ER.


Description:

Over the next year between 20 and 40 patients, who meet all inclusion and exclusion criteria, will be entered into the study. The treatment period of the study will last at least 10-13 weeks depending on how quickly your Depakote ER level reaches a therapeutic level (50-100mcg/mL).

At your first visit:

- A medical and psychiatric history will be obtained. For your own safety, it is your responsibility to tell the study doctor or study staff of your past and present diseases, all allergies and medical conditions, and all medications that you currently or recently have taken, including over-the-counter medications such as vitamins, allergy medicines, and herbal drugs. A physical examination and vital signs, which will include measuring your height, weight, blood pressure, respiratory (breathing) rate, and heart rate (pulse).

- Blood samples will be taken, through a needle in your vein. Approximately 2-2 ½ tablespoons (28 or 38 ml) of blood for routine testing of hematology (red and white blood cells) and clinical chemistry (blood salt, sugar, fats, and hormones, and tests of liver, kidney and thyroid function), and valproate level

- A urinalysis, a urine pregnancy test (for all females), and a urine drug screen will be obtained. If you are a woman and your urine pregnancy test is positive, a blood test will be done to confirm this; you will not be able to participate in this study if this is also positive.

- An electrocardiogram (ECG - a painless electrical tracing of your heart function).

- Psychiatric scales designed to measure past compliance, side-effects, and your bipolar symptoms will be administered. (See the Attached Schedule of Events for a list of all Procedures required during the study) Patients, who continue to meet all inclusion and exclusion criteria, will return for a baseline visit (Visit 2). At this visit you will discontinue valproic acid and begin taking Depakote ER the following day. The total daily dose will be adjusted to be 8-20% higher than your original valproic acid dose, at the discretion of the Investigator, in order to reach therapeutic levels. Rating scales will be administered and the study drug (Depakote ER) will be dispensed.

Your study doctor or staff will explain the amount of medication you will receive, and will give you instructions on how to take it. It is important that your study drug is not taken by anyone else. Your study doctor and other study staff, whom you are to ask any questions about the study drug's effects and any side effects, will regularly check your response to treatment. If you get worse, the study drug dose may be changed, or you may be given additional medications, or the study drug may be stopped and you will be given another drug instead.

Before continuing to visit 3 you must reach a valproate level of 50-100mcg/mL. Weekly titration visits (T1-T4) will be scheduled and blood samples will be taken to test the Valproic level in your blood. The study doctor may adjust your dose, until a level of 50-100 mcg/ml is reached. If the above level is not reached within four weeks of visit 2, you will be discontinued from the study.

After the therapeutic level is reached, you will be asked to return in one week for visit 3, four weeks for visit 4, and another four weeks for the final visit, visit 5. Overall, your treatment with Depakote ER will be between 10-13 weeks in duration. During visits 3 and 4 the Depakote ER dose may be adjusted in 250mg or 500mg increments to maintain adequate level, to manage side effects and/or manage bipolar symptoms at the discretion of the study doctor. In addition, you will be asked to report any side effects and complete the psychiatric scales at each visit and blood samples will be taken at visits 3 and 5. (See the Schedule of Events for more details)


Recruitment information / eligibility

Status Completed
Enrollment 20
Est. completion date September 2006
Est. primary completion date July 2006
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Bipolar I and II patients, age 18 and older, currently tolerating a stable dose of Valproic Acid for at least 3 months with a current Valproic Acid level of at least 50 mcg/mL at screening and baseline,

Exclusion Criteria:

- Women who are pregnant or breast feeding or intending to become pregnant, contraindication or history of hypersensitivity to valproic acid, DVPX or DVPX ER.

- Clinically significant organ disease, clinically significant abnormalities in physical examination, EKG, or lab test, history of any disease which in the investigator's opinion may confound the results of the study or pose additional risk.

- Other principle nonpsychotic or psychotic psychiatric diagnosis. Patients weighing >300 pounds.

- Patients taking any other mood stabilizers.

- Patients not already on a stable dose of valproic acid or have a Valproic Acid level less than 50 mcg/mL at screening.

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Valproic Acid and Depakote ER


Locations

Country Name City State
United States Cosme Lozano M.D. Joliet Illinois

Sponsors (2)

Lead Sponsor Collaborator
Joliet Center for Clinical Research Abbott

Country where clinical trial is conducted

United States, 

References & Publications (1)

Berk, M & Berk, L. (2004). Mood stabilizers and treatment adherence in bipolar disorder: addressing adverse events. Bowden C.L., Calabrese J.R., McElroy S.L., Gyulai L., Wassef A., Petty F., Pope H.G. Jr, Chou J.C., Keck P.E. Jr, Rhodes L.J., Swann A.C., Hirschfeld R.M., Wozniak P.J., (2000). Valproate in the treatment of acute mania: placebo-controlled study. Archives of General Psychiatry, 48, 62-68. Pope, S. J. (2002). Nonadherence with mood stabilizers: prevalence and predictors. Journal of Clinical Psychiatry, 63, 384-90. Sajatovic, M., Davies M., & Hrouda, D.R. (2004). Enhancement of treatment adherence with patients with bipolar disorder. Psychiatric Services, 55(3), 264-69. Depakote ER package insert, Abbott Laboratories, 2002.

Outcome

Type Measure Description Time frame Safety issue
Primary Primary Measure: Safety and Tolerability.
Primary Comparisons will be made between baseline and final measures of adverse events and UKU results.
Secondary Secondary Measures: Compliance and efficacy.
Secondary Comparison of YMRS and MADRS scores
See also
  Status Clinical Trial Phase
Completed NCT00001919 - Neuroimaging of St. John's Wort-Induced Changes of Serotonin Metabolism in Normal Subjects N/A
Completed NCT00026832 - Examination of Brain Serotonin Receptors in Patients With Mood Disorders
Completed NCT01951508 - Effects of Methylphenidate, Modafinil, and MDMA on Emotion-processing in Humans: A Pharmaco-fMRI Study Phase 0
Terminated NCT01830088 - Family Based Treatment of Depressed Adolescents (AHUS) N/A
Completed NCT01269710 - Second-Generation Antipsychotic Treatment Indication Effectiveness And Tolerability In Youth (Satiety) Study N/A
Completed NCT00001146 - Omega-3 Fatty Acids in the Treatment of Bipolar Disorder: A Double-Blind, Placebo-Controlled Trial Phase 2
Completed NCT00001170 - Study of the Psychological Development of Children of Parents With and Without Affective Disorders N/A
Completed NCT00001192 - Neuropsychological Evaluation of Psychiatric and Neurological Patients N/A
Completed NCT02189057 - A Pharmacokinetic/Pharmacodynamic Genetic Variation Treatment Algorithm Versus Treatment As Usual for Management Of Depression N/A
Completed NCT01473550 - Mental Health Engagement Network (MHEN) N/A
Completed NCT00990067 - Interaction Between Duloxetine and 3,4-Methylenedioxymethamphetamine (MDMA, Ecstasy) Phase 1
Completed NCT00794040 - A Controlled Trial of Serotonin Reuptake Inhibitors Added to Stimulant Medication in Youth With Severe Mood Dysregulation Phase 2
Completed NCT02819986 - Effectiveness of Using the Progressive Goal Attainment Program in Anxiety and Mood Disorders N/A
Completed NCT03538860 - Validation of an Automated Online Language Interpreting Tool - Phase Two. N/A
Completed NCT00016731 - Adolescence, Puberty, and Emotion Regulation
Completed NCT02721316 - Outpatient Nurse Monitoring Under the Prevention of Recurrent Suicidal N/A
Recruiting NCT02443636 - The Canadian Depression Research and Intervention Network (CDRIN) Maritimes Registry
Terminated NCT01493323 - Functional Imaging of Psychic Pain N/A
Completed NCT00699218 - A Pilot Study on Repetitive Transcranial Magnetic Stimulation (rTMS) Treatment of Bipolar Depression N/A
Completed NCT00001654 - The Role of Emotion in the Development of Psychopathology N/A

External Links